Thermo Fisher Scientific Q3 2026 Earnings Analysis
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Thermo Fisher Scientific Q3 2026 Earnings Analysis
-
Letto da:
-
Di:
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Thermo Fisher Scientific's third quarter 2026 results — and Jordan, this is a good one.
**JORDAN:** Oh, it's a good one. Beat and raise, strong end markets, tariff refunds... there's a lot to unpack.
**ALEX:** There really is. But before we get into it — quick reminder for everyone listening: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Important stuff, let's get into the numbers.
**ALEX:** Okay, so headline numbers first. Revenue came in at $12.14 billion, up 9% year-over-year. Adjusted EPS grew 15% to $6.68 per share. And adjusted operating margin expanded 120 basis points to 24.5%.
**JORDAN:** And here's the thing — this wasn't just "in line" or a small beat. CFO Jim Meyer said Q3 revenue came in more than $200 million ahead of their prior guidance, and EPS beat by $0.26. That's a real beat.
**ALEX:** Right, and there's an interesting wrinkle in that EPS beat. $0.08 came from genuinely strong operational execution, $0.03 from foreign exchange, but $0.15 — more than half — came from tariff refunds that got recovered in the quarter.
**JORDAN:** Yeah, that tariff refund piece is worth sitting with for a second. Management said they received approvals on the vast majority of their total potential refund claims this quarter. That added about $60 million to adjusted operating income — roughly 50 basis points of margin. But here's what I liked: they didn't just drop it straight to the bottom line. They reinvested a chunk of it into AI deployment, capacity scale-up in Pharma Services, and employee investments.
**ALEX:** Which tells you management is thinking medium-term, not just trying to make this quarter look good.
**JORDAN:** Exactly. It's a one-time windfall, and they treated it like one — put it to work rather than just banking it.
**ALEX:** Let's talk end markets, because this is really the heart of the story. Pharma and biotech — their biggest and most important market — grew high single digits, led by Pharma Services and the research and safety channel. Academic and government was flat, which was expected. Industrial and applied grew high single digits, driven by electron microscopy and semiconductor demand. And diagnostics and healthcare grew low single digits.
**JORDAN:** The pharma and biotech story is the one analysts kept circling back to in the Q&A. CEO Marc Casper talked about this almost like a staged recovery — first you saw clinical trial authorizations pick up, then lab-based research activity in biotech, and now they're expecting the high-end reagents business to be the next leg of that recovery over the next couple of quarters.
**ALEX:** It's basically a domino effect working through the biotech funding recovery.
**JORDAN:** And geographically, Asia Pacific — including China — grew low double digits. That's notable. China's been a wildcard for a lot of life sciences companies, and Thermo's seeing real strength there.
**ALEX:** Now let's talk strategy, because there were some real moves this quarter. The Clario acquisition — that's the clinical research technology business — integration is going smoothly, and management's already talking about revenue synergies building.
**JORDAN:** They also hit the one-year anniversary of the filtration and separation business acquisition, which they said strengthened their bioproduction capabilities. And on the flip side, they completed the divestiture of the microbiology business — which actually dragged reported revenue down about 1 point, but it's part of streamlining the portfolio toward higher-growth areas.
**ALEX:** Classic port
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione